Osteogenesis Imperfecta Treatment Market Report 2026

Osteogenesis Imperfecta Treatment Market Overview

• Osteogenesis Imperfecta Treatment market size has reached to $0.93 billion in 2025 • Expected to grow to $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.3% • Growth Driver: Increasing Prevalence Of Osteogenesis Imperfecta Fueling The Growth Of The Market Due To Improved Diagnosis And Patient Registries • Market Trend: Advanced Therapeutics With Monoclonal Antibodies For OI Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Osteogenesis Imperfecta Treatment Market?

Osteogenesis imperfecta treatment refers to the range of medical, surgical, and supportive interventions aimed at managing the symptoms, improving bone strength, reducing fracture risk, and enhancing the quality of life of individuals affected by osteogenesis imperfecta (OI), a genetic disorder characterized by brittle bones. The main treatment types for osteogenesis imperfecta treatment are medication, surgery, physical therapy, and lifestyle modifications. Medication refers to the use of pharmaceutical drugs to manage or treat medical conditions. In osteogenesis imperfecta (OI), medications such as bisphosphonates, teriparatide, or monoclonal antibodies help strengthen bones and reduce fracture frequency. Different drug classes include teriparatide, denosumab, and others, provided through various routes of administration, including subcutaneous, intravenous, oral, and others. These treatments are provided through varied distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies to a variety of end users, including hospitals, homecare settings, specialty clinics, and other healthcare providers.

What Is The Osteogenesis Imperfecta Treatment Market Growth Forecast?

The osteogenesis imperfecta treatment market size is expected to see steady growth in the next few years. It will grow to $1.16 billion in 2030 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to development of novel drugs and hormone therapies, advancements in minimally invasive rodding and spinal surgeries, integration of telemedicine in homecare, increasing focus on patient-centric lifestyle and rehabilitation programs, rising adoption of precision medicine approaches. Major trends in the forecast period include increased adoption of bisphosphonate and teriparatide therapies, growth in rodding and spinal fusion surgeries, rising demand for personalized physical therapy programs, expansion of homecare and specialty clinic services, enhanced focus on patient education and lifestyle management.

Global Osteogenesis Imperfecta Treatment Market Segmentation

1) By Treatment Type: Medication, Surgery, Physical Therapy, Lifestyle Modifications 2) By Drug Class: Teriparatide, Denosumab, Other Drug Classes 3) By Route Of Administration: Subcutaneous, Intravenous, Oral, Other Routes Of Administration 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 5) By End-User: Hospitals, Homecare, Specialty Clinics, Other End Users Subsegments: 1) By Medication: Bisphosphonates, Teriparatide, Hormone Replacement Therapy, Pain Relievers, Calcium And Vitamin D Supplements 2) By Surgery: Rodding Surgery, Spinal Fusion Surgery, Fracture Repair Surgery, Joint Replacement Surgery 3) By Physical Therapy: Strength Training, Range Of Motion Exercises, Aquatic Therapy, Gait Training, Assistive Device Training 4) By Lifestyle Modifications: Nutritional Counseling, Fall Prevention Strategies, Home Environment Modification, Activity Modification, Patient Education And Support Programs

What Is The Driver Of The Osteogenesis Imperfecta Treatment Market?

The increasing prevalence of osteogenesis imperfecta (OI) is expected to propel the growth of the osteogenesis imperfecta treatment market going forward. Osteogenesis imperfecta is a genetic disorder characterized by fragile bones that break easily, affecting individuals across all age groups. The rise in osteogenesis imperfecta prevalence is due to advances in genetic testing and the establishment of national and regional disease registries, which are identifying previously undiagnosed cases. The osteogenesis imperfecta treatment supports patients by providing therapies such as bisphosphonates, intramedullary rods, braces, and supportive services that improve bone strength and quality of life. For instance, in July 2025, according to the Oxford Academic, a UK-based academic research platform, among 5,722 individuals with two or more osteogenesis imperfecta (OI)–related medical claims at least 30 days apart, 2,095 met the CE eligibility criteria and constituted the overall OI cohort. Therefore, the increasing prevalence of OI is driving the growth of the osteogenesis imperfecta treatment industry.

Key Players In The Global Osteogenesis Imperfecta Treatment Market

Major companies operating in the osteogenesis imperfecta treatment market are Amgen Inc., Ascendis Pharma A/S, Mereo BioPharma Group PLC, OrthoPediatrics Corp., Ultragenyx Pharmaceutical Inc., BioMarin Pharmaceutical Inc., PTC Therapeutics Inc., Kyowa Kirin Co. Ltd., Ipsen S.A., Alexion Pharmaceuticals (AstraZeneca Rare Disease), Takeda Pharmaceutical Company Limited, Novartis AG (Bone Metabolism Portfolio), Roche Holding AG (Genentech), Sun Pharmaceutical Industries Ltd., Cipla Ltd., Dr. Reddy’s Laboratories Ltd., Aurobindo Pharma Ltd., Teva Pharmaceutical Industries Ltd., Apotex Inc., Stada Arzneimittel AG, Fresenius Kabi AG, Alkem Laboratories Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Glenmark Pharmaceuticals Ltd., Pfizer Inc., Viatris Inc., Accord Healthcare Ltd., Sandoz Group AG, Medtronic plc, Smith & Nephew plc, Zimmer Biomet Holdings Inc.

Global Osteogenesis Imperfecta Treatment Market Trends and Insights

Major companies operating in the osteogenesis imperfecta treatment market are focusing on advanced therapeutics such as sclerostin inhibition therapy to accelerate bone formation and reduce fracture risk in patients with osteogenesis imperfecta (OI). Sclerostin inhibition therapy involves the use of monoclonal antibodies to block sclerostin, a protein that restricts bone growth, thereby promoting increased bone mineral density and strength. For instance, in October 2024, Ultragenyx Pharmaceutical Inc., a US-based biopharmaceutical company, received Breakthrough Therapy Designation from the FDA for its investigational therapy setrusumab (UX143). Setrusumab is a fully human monoclonal antibody designed to inhibit sclerostin, which in turn stimulates new bone formation and enhances bone strength, aiming to reduce fracture risk in patients with OI Types I, III, and IV aged two years and older.

What Are Latest Mergers And Acquisitions In The Osteogenesis Imperfecta Treatment Market?

In May 2023, Abiogen Pharma S.p.A., an Italy-based pharmaceutical company, acquired a 97.09% stake in EffRx Pharmaceuticals SA, a Swiss specialty pharma company. With this acquisition, Abiogen aims to accelerate its international expansion and strengthen its bone-disease portfolio, particularly in musculoskeletal and rare conditions. EffRx Pharmaceuticals SA is a Switzerland-based company that develops and markets prescription drugs for musculoskeletal and rare diseases.

Regional Insights

North America was the largest region in the osteogenesis imperfecta treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Osteogenesis Imperfecta Treatment Market?

The osteogenesis imperfecta treatment market consists of revenues earned by entities by providing services such as physical therapy, occupational therapy, and orthopedic support. The market value includes the value of related goods sold by the service provider or included within the service offering. The osteogenesis imperfecta treatment market also includes sales of bisphosphonates, intramedullary rods, and braces and splints. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Osteogenesis Imperfecta Treatment Market Report 2026?

The osteogenesis imperfecta treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the osteogenesis imperfecta treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.